Oncolytic Viruses Armed with Multiple Immunomodulatory Transgenes in Cancer Immunotherapy
Human Gene Therapy · 20.11.2026
DOI: 10.1177/10430342261506071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy, online erschienen am 20.11.2026. Verfasst von Md Iftehimul und 8 weiteren Autor:innen. Die Arbeit nennt 95 Literaturangaben. Gefördert von: National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Oncolytic viruses (OVs) have emerged as versatile cancer immunotherapeutic agents that selectively kill tumor cells while simultaneously inducing antitumor immune responses. The therapeutic activity of OVs can be further enhanced by arming them with immunomodulatory transgenes. However, expression of a single transgene often fails to generate durable antitumor immunity, largely because of the complex, immunosuppressive nature of the tumor microenvironment (TME). To overcome this limitation, recent advances in OV engineering have focused on co-expression of multiple immunomodulatory payloads, including a combination of cytokines, cytokine receptors, costimulatory molecules, chemokines, immune checkpoint inhibitors (ICIs), bispecific T-cell engagers, viral antigens, and tumor antigens. Increasing evidence indicates that multi-transgene-armed OVs can more effectively promote dendritic cell maturation, enhance intratumoral infiltration and activation of CD8 + T cells and natural killer cells, elevate effector-to-regulatory T-cell ratios, remodel immunosuppressive TMEs, and synergize with other immunotherapies, including ICI and adoptive cell therapy. Despite growing interest in this field, a comprehensive review focused specifically on the immunological mechanisms, therapeutic efficacy, and translational challenges of multi-transgene-expressing OVs remains lacking. In this review, we summarize multi-transgene-armed OVs, highlighting the mechanistic rationale underlying transgene combinations, outlining their antitumor effects across preclinical settings, and discussing key design principles for next-generation OV-based immunotherapies.
Förderung
- National Institute of General Medical Sciences
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Iftehimul, M., Wang, H., Chakraborty, S., Wiernicki, S., Rorie, C. J., Newman, R. H., Kaufman, H. L., Rabkin, S. D., & Saha, D. (2026). Oncolytic Viruses Armed with Multiple Immunomodulatory Transgenes in Cancer Immunotherapy. Human Gene Therapy. https://doi.org/10.1177/10430342261506071
Vancouver
Iftehimul M, Wang H, Chakraborty S, Wiernicki S, Rorie CJ, Newman RH, et al. Oncolytic Viruses Armed with Multiple Immunomodulatory Transgenes in Cancer Immunotherapy. Human Gene Therapy. 2026. doi:10.1177/10430342261506071
BibTeX
@article{Iftehimul2026,
author = {Iftehimul, Md and Wang, Hongbin and Chakraborty, Sourav and Wiernicki, Stanley and Rorie, Checo J. and Newman, Robert H. and Kaufman, Howard L. and Rabkin, Samuel D. and Saha, Dipongkor},
title = {Oncolytic Viruses Armed with Multiple Immunomodulatory Transgenes in Cancer Immunotherapy},
journal = {Human Gene Therapy},
year = {2026},
doi = {10.1177/10430342261506071}
}
EUVIMED